Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José María Mora-Rodríguez, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 2026-2026
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Construction and Application of an Easy-To-Use Assay for the Screening of Human DPP IV Inhibitors in Living Cell System
Shu‐Mei Pan, C. Xing, Hongwei Li, et al.
(2025)
Closed Access
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, et al.
Future Virology (2023) Vol. 18, Iss. 5, pp. 321-333
Open Access | Times Cited: 20
A Review of Hyperglycemia in COVID-19
Maryam Zahedi, Saba Kordrostami, Mohammadreza Kalantarhormozi, et al.
Cureus (2023)
Open Access | Times Cited: 17
Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19
Jenny Garmendia, Alexis García, Claudia Valentina De Sanctis, et al.
Current Issues in Molecular Biology (2022) Vol. 45, Iss. 1, pp. 33-50
Open Access | Times Cited: 24
Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
Jiaman Du, Jiewen Fu, Wenqian Zhang, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 3
Open Access | Times Cited: 13
Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions
Juan Fernando Padín, José Manuel Pérez‐Ortiz, Francisco Javier Redondo Calvo
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7209-7209
Open Access | Times Cited: 3
Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections
Shailendra Mani, Anupamjeet Kaur, Kamini Jakhar, et al.
International Journal of Biological Macromolecules (2023) Vol. 245, pp. 125444-125444
Open Access | Times Cited: 8
Spotlight on contributory role of host immunogenetic profiling in SARS-CoV-2 infection: Susceptibility, severity, mortality, and vaccine effectiveness
Somayeh Yazdanparast, Mehdi Bakhtiyaridovvombaygi, Fatemeh Mikanik, et al.
Life Sciences (2023) Vol. 328, pp. 121907-121907
Open Access | Times Cited: 7
DrugRep-HeSiaGraph: when heterogenous siamese neural network meets knowledge graphs for drug repurposing
Zahra Ghorbanali, Fatemeh Zare‐Mirakabad, Najmeh Salehi, et al.
BMC Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Seroprevalence of SARS-CoV-2 and Hepatitis B Virus Coinfections among Ethiopians with Acute Leukemia
Jemal Alemu, Balako Gumi, Aster Tsegaye, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1606-1606
Open Access | Times Cited: 1
SARS‐CoV‐2, periodontal pathogens, and host factors: The trinity of oral post‐acute sequelae of COVID‐19
Joel Schwartz, Kristelle J. Capistrano, Joseph L. Gluck, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 3
Open Access | Times Cited: 1
A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern
Michela Murdocca, Isabella Romeo, Gennaro Citro, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 891-891
Open Access | Times Cited: 1
An overview of the development of pharmacotherapeutics targeting SARS-CoV-2
Tom Lucaj, Ian Hay, Amirreza Samarbakhsh, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 9, pp. 104126-104126
Closed Access | Times Cited: 1
Neurological Sequelae of Post-COVID-19 Fatigue: A Narrative Review of Dipeptidyl Peptidase IV-Mediated Cerebrovascular Complications
Che Mohd Nasril Che Mohd Nassir, Muhammad Danial Che Ramli, Usman Jaffer, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 12, pp. 13565-13582
Open Access | Times Cited: 1
Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use
Д. В. Куркин, Д. А. Бакулин, Е. И. Морковин, et al.
Pharmacy & Pharmacology (2023) Vol. 11, Iss. 1, pp. 19-47
Open Access | Times Cited: 3
Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV
Rohani, Ellin Febrina, Indah Suasani Wahyuni, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 3473-3491
Open Access | Times Cited: 3
Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)
José María Mora-Rodríguez, Belén G. Sánchez, Alicia Bort, et al.
Life Sciences (2023) Vol. 336, pp. 122292-122292
Open Access | Times Cited: 3
Overview of the cardio-metabolic impact of the COVID-19 pandemic
Maryam Barkhordarian, Arezoo Behbood, Maryam Ranjbar, et al.
Endocrine (2023) Vol. 80, Iss. 3, pp. 477-490
Open Access | Times Cited: 2
Discovery of components in honeysuckle for treating COVID-19 and diabetes based on molecular docking, network analysis and experimental validation
Feng Xu, Ya Qin, Changxiu Guan
Natural Product Research (2024), pp. 1-5
Open Access
The Potential for Multi-Disease Treatment: Applications of Dipeptidyl Peptidase Inhibitors
甜甜 李
Advances in Clinical Medicine (2024) Vol. 14, Iss. 07, pp. 1469-1477
Closed Access
The treatment of COVID-19: lessons learned and future directions
Michael Cenname, Matthew W. McCarthy
Future Virology (2024) Vol. 19, Iss. 8-9, pp. 315-323
Closed Access
Multiple Mechanisms of Action of Sulfodyne®, a Natural Antioxidant, against Pathogenic Effects of SARS-CoV-2 Infection
Paul‐Henri Roméo, Laurine Conquet, Sébastien Messiaen, et al.
Antioxidants (2024) Vol. 13, Iss. 9, pp. 1083-1083
Open Access
Predictive Modeling and Drug Repurposing for Type-II Diabetes
Nitin Wankhade, Anju Sharma, Mushtaq Ahmad Wani, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 11, pp. 1907-1917
Closed Access
Bioinformatic characterization of ENPEP, the gene encoding a potential cofactor for SARS-CoV-2 infection
Antti Arppo, Harlan Barker, Seppo Parkkila
PLoS ONE (2024) Vol. 19, Iss. 12, pp. e0307731-e0307731
Open Access
Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis
Denis Delić, Thomas Klein, Christian T. Wohnhaas, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117778-117778
Open Access
Page 1 - Next Page

Scroll to top